newsfilter
← Latest News
GlobeNewswire·

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

– Transaction valued at $250 million, with up to $14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercialization across Europe – –